ClinConnect ClinConnect Logo
Search / Trial NCT02077621

Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer

Launched by PHYTOHEALTH CORPORATION · Mar 2, 2014

Trial Information

Current as of June 06, 2025

Withdrawn

Keywords

Cancer Related Fatigue Palliative Abdominal Surgery Hrql

ClinConnect Summary

This will be a double-blind, randomized, and placebo-controlled study. At least 40 evaluable patients who are scheduled for palliative abdominal surgery for cancer will be randomly assigned to the control or treatment group. Each group will have at least 20 patients and be treated as follows: 1) control group: patients will accept placebo 1 dose a day (POD-1) before surgery and 1 dose a day for 3 days after surgery (POD+0 to POD+2); 2) treatment group: patients will accept PG2 1 dose a day (POD-1) before surgery and 1 dose a day for 3 days after surgery (POD+0 to POD+2).

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients who have cancer and are scheduled for palliative abdominal surgery for cancer
  • Age \> 20 years older
  • Patients who signed the informed consent form
  • Exclusion Criteria:
  • Patients, at screening, has levels greater than 2.5 times the upper limit of normal liver function of alanine aminotransferase or aspartate aminotransferase.
  • Patients has a severe renal impairment (defined as serum creatinine greater than 2 times the upper limit of normal or BUN greater than 2.5 times the upper limit of normal for range); or the subject is on dialysis.
  • Patients have ongoing infection, respiratory tract dysfunction, cardiac dysfunction or immune disorder that, in the opinion of the investigator, may interfere with conduct of the study.
  • Patients who are not suitable for undergoing surgery (e.g. congenital hemostatic disorders) by the investigator's judgment.
  • Patients have enrolled or have not yet completed other investigational drug trials within 1 month before screening.
  • Female patients are pregnant or breast-feeding.
  • Patients who require preoperative nutritional support
  • Patients with serious comorbidities (American Society of Anesthesiologists Risk Class of 4 or 5).
  • Patients who is unwilling or unable to answer the quality of life questionnaires i.e. the BFI-T and EORTC QLQ-C30.

About Phytohealth Corporation

PhytoHealth Corporation is a leading biopharmaceutical company dedicated to advancing innovative therapies derived from plant-based compounds. With a strong commitment to research and development, PhytoHealth focuses on harnessing the potential of phytomedicine to address unmet medical needs across various therapeutic areas. The company prioritizes rigorous clinical trials and scientific validation to ensure the safety and efficacy of its products, aiming to improve patient outcomes and enhance the quality of life. Through collaboration with academic institutions and healthcare professionals, PhytoHealth is at the forefront of transforming traditional medicine into evidence-based solutions.

Locations

Taipei, , Taiwan

Taipei, , Taiwan

Patients applied

0 patients applied

Trial Officials

Jin-Ming Wu, M.D.

Principal Investigator

National Taiwan University Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials